Vertex Pharmaceuticals Incorporated
NASDAQVertex Pharmaceuticals enters September with a notable upgrade from Wall Street's most closely watched desks — and options traders are finally moving in the same direction as the bulls. The standout event this week is Morgan Stanley's reinstatement of VRTX at Overweight with a $665 price target, filed by analyst Terence Flynn on September 2. That target sits roughly 21% above the…
Snapshot as of 20 Sept 2026
Vertex Pharmaceuticals enters September with a notable upgrade from Wall Street's most closely watched desks — and options traders are finally moving in the same direction as the bulls. The standout event this week is…
VRTX enters the post-earnings week with analysts uniformly raising price targets even as the stock remains nearly 10% below where most of them see fair value — a gap that frames the next few months as a test of whether…
Vertex Pharmaceuticals enters the back half of June in a quiet but telling configuration — the stock is down nearly 1% on the week and off 75% over the past month, while options traders are quietly moving away from the…
VRTX heads into its Q1 2026 results — scheduled for May 13 — with options traders at their most defensive in months, even as the Street raised price targets and the lending market remains wide open. The clearest signal…
Vertex Pharmaceuticals arrives at its May 4 Q1 2026 earnings report carrying a 28.5% gap between where the stock trades and where most analysts believe it belongs. The bullish analyst thesis remains firmly intact…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VRTX — free to start on ORTEX.
Sign up for free →Open VRTX on ORTEX